tipifarnib has been researched along with pamidronate in 1 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (pamidronate) | Trials (pamidronate) | Recent Studies (post-2010) (pamidronate) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 2,220 | 368 | 444 |
| Protein | Taxonomy | tipifarnib (IC50) | pamidronate (IC50) |
|---|---|---|---|
| Farnesyl pyrophosphate synthase | Homo sapiens (human) | 1.0745 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbruzzese, A; Budillon, A; Caraglia, M; Colao, A; D'Alessandro, AM; Giuberti, G; Marra, M; Prete, SD; Tagliaferri, P; Tassone, P; Venuta, S; Viscomi, C; Vitale, G | 1 |
1 other study(ies) available for tipifarnib and pamidronate
| Article | Year |
|---|---|
The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate.
Topics: Alkyl and Aryl Transferases; Apoptosis; Caspases; Cell Division; Diphosphonates; Drug Synergism; Enzyme Inhibitors; Epidermal Growth Factor; Farnesyltranstransferase; Humans; Imidazoles; KB Cells; Mitogen-Activated Protein Kinases; Pamidronate; Protein Prenylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinolones; Zoledronic Acid | 2004 |